Showing 8,461 - 8,480 results of 15,870 for search '(( six ((we decrease) OR (a decrease)) ) OR ( i ((largest decrease) OR (larger decrease)) ))', query time: 0.96s Refine Results
  1. 8461
  2. 8462

    Validation of microarray data with TaqMan RT-PCR of selected differentially expressed genes. by Nicholas A. Ettinger (124079)

    Published 2008
    “…Relative expression of infected samples is displayed in reference to a line at y = 1, signifying no change. Bars below y = 1 signify genes that have decreased expression relative to uninfected samples. …”
  3. 8463

    Data Sheet 1_Exploring AI-personalized visualization of the safe place in virtual reality versus imagination of the safe place for stress, burnout, and relaxation in psychotherapis... by Viktoria Wollweber (22651739)

    Published 2025
    “…</p>Methods<p>Five psychotherapists from an outpatient setting participated in a six-week, within-subject study that used an alternating treatments design (ABCABC) which was created via a participatory approach where participants actively engaged in the planning of the study. …”
  4. 8464

    Network analysis of pig movements: Loyalty patterns and contact chains of different holding types in Denmark by Jana Schulz (4183195)

    Published 2017
    “…The total number of active holdings as well as the number of pig movements decreased during the study period while the holding sizes increased. …”
  5. 8465

    Image_1_Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.tif by Xiaofeng Chen (392939)

    Published 2022
    “…</p>Methods and Materials<p>Pathologically-proven advanced HCC patients received sintilimab (200 mg) on day 1 and anlotinib (12 mg) once daily on days 1 to 14 every 3 weeks, with a safety run-in for the first six participants to assess dose-limiting toxicities (DLTs). …”
  6. 8466

    Image_2_Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.tif by Xiaofeng Chen (392939)

    Published 2022
    “…</p>Methods and Materials<p>Pathologically-proven advanced HCC patients received sintilimab (200 mg) on day 1 and anlotinib (12 mg) once daily on days 1 to 14 every 3 weeks, with a safety run-in for the first six participants to assess dose-limiting toxicities (DLTs). …”
  7. 8467

    Table_1_Safety and Efficacy of Sintilimab and Anlotinib as First Line Treatment for Advanced Hepatocellular Carcinoma (KEEP-G04): A Single-Arm Phase 2 Study.docx by Xiaofeng Chen (392939)

    Published 2022
    “…</p>Methods and Materials<p>Pathologically-proven advanced HCC patients received sintilimab (200 mg) on day 1 and anlotinib (12 mg) once daily on days 1 to 14 every 3 weeks, with a safety run-in for the first six participants to assess dose-limiting toxicities (DLTs). …”
  8. 8468

    The Tree GSPF Level Tree Chronogram of Poison Frogs with Known Taxonomic Diversity (i.e., Numbers within Parentheses) and Significant Diversification Rate Changes for Nodes or Line... by Juan C Santos (267336)

    Published 2009
    “…<p>Taxonomic diversity is indicated by the species sampled in our study (left number) and the total number of species described per group or genus (right number) (upward arrow indicates rate increase, and downward indicates rate decrease). The highest diversification increase (node 1) corresponds to the widespread <i>Ameerega</i> lineage that rapidly expanded into Amazonian since the late Miocene. …”
  9. 8469

    Effects of experimental treatments on by Christopher A. Gabler (301169)

    Published 2013
    “…<p><b>six metrics of </b><b><i>Triadica</i></b><b> size.…”
  10. 8470

    DataSheet_1_Including Volume Effects in Biological Treatment Plan Optimization for Carbon Ion Therapy: Generalized Equivalent Uniform Dose-Based Objective in TRiP98.pdf by Marco Battestini (12268814)

    Published 2022
    “…In conclusion, this novel optimization method can be applied to different OARs, but it achieves the largest improvement for organs whose volume effect is larger. …”
  11. 8471

    Membrane topology of murine FIT2 and FIT1. by David A. Gross (143464)

    Published 2010
    “…<p><b>A and C</b>, FIT2 and FIT1 topological models with N- and C-termini oriented toward the cytosol and six transmembrane domains with a large second luminal loop. …”
  12. 8472

    Hand and pace effects on deoxygenated hemoglobin concentration changes (ΔHHb) during basketball slalom dribbling task. by Daniel Carius (9339246)

    Published 2020
    “…B: * indicates a significant influence of factor pace on ΔHHb (C1-Cz: F(1, 130) = 10.47, p = .002, ξ = .42; p-FDR = .002), indicating a larger ΔHHb decrease across all participants during fast dribbling with dominant hand as compared to slow dribbling with DH in contralateral PMC-SMA (Post-hoc, C1-Cz: t(11) = 3.97, p = .002, ξ = .65).…”
  13. 8473

    Time-Dependent Long-Range-Corrected Double-Hybrid Density Functionals with Spin-Component and Spin-Opposite Scaling: A Comprehensive Analysis of Singlet–Singlet and Singlet–Triplet... by Marcos Casanova-Páez (7158320)

    Published 2021
    “…For singlet–singlet excitations, we cross-validate them on six benchmark sets that cover small to medium-sized chromophores with different excitation types (local-valence, Rydberg, and charge transfer). …”
  14. 8474

    Time-Dependent Long-Range-Corrected Double-Hybrid Density Functionals with Spin-Component and Spin-Opposite Scaling: A Comprehensive Analysis of Singlet–Singlet and Singlet–Triplet... by Marcos Casanova-Páez (7158320)

    Published 2021
    “…For singlet–singlet excitations, we cross-validate them on six benchmark sets that cover small to medium-sized chromophores with different excitation types (local-valence, Rydberg, and charge transfer). …”
  15. 8475

    Discovery and Characterization of Novel Vascular and Hematopoietic Genes Downstream of <em>Etsrp</em> in Zebrafish by Gustavo A. Gomez (265864)

    Published 2009
    “…Subsequent in vivo expression studies resulted in the identification of fourteen genes with blood and/or vascular expression, six of these being completely novel. Regulation of these genes by <em>etsrp</em> was confirmed by ectopic induction in <em>etsrp</em> overexpressing embryos and decreased expression in <em>etsrp</em> deficient embryos. …”
  16. 8476
  17. 8477
  18. 8478

    Acute phase CHIKV disease was associated with high levels of IL-6, CXCL9, CCL2, CXCL10. by Alyson A. Kelvin (132909)

    Published 2013
    “…<p>Cytokine Bead Array analysis of CHIKV patient serum samples showed high levels of IL-6, CXCL9, CCL2 and CXCL-10 are associated with acute disease phase and decreased with patient convalescence. Six-month and one-year cytokine levels were analysed for statistical significance using the Wilcoxon test for Significance by comparing with acute levels. …”
  19. 8479

    Venn diagram and UpsetR plot of switch genes from different brain regions. by Judith A. Potashkin (7419101)

    Published 2019
    “…The vertical bars at the top show the size of the corresponding intersection, ranked by decreasing set size, where a gray dot indicates an empty set and a single black dot indicates no intersection with another set.…”
  20. 8480

    Acute changes in cortical activation during active ankle movement after whole-body vibration for spasticity in hemiplegic legs of stroke patients: a functional near-infrared spectr... by Kodai Miyara (7344392)

    Published 2019
    “…<p><b>Background</b>: A recent study revealed that whole-body vibration (WBV) tends to decrease spasticity in stroke-related hemiplegic legs. …”